Safety of shortened infusion times for combined ipilimumab and nivolumab.
Gassenmaier M, Lipp HP, Scheu A, Wagner NB, Kofler L, Mueller A, Doecker D, Eigentler TK, Garbe C, Forschner A.
Gassenmaier M, et al. Among authors: scheu a.
Cancer Immunol Immunother. 2018 Jan;67(1):135-140. doi: 10.1007/s00262-017-2075-y. Epub 2017 Oct 7.
Cancer Immunol Immunother. 2018.
PMID: 28988363